Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACT-709478 + midazolam
- Development stage
- Unknown
- Lead developer
- Neurocrine Biosciences
- Modality
- Small Molecules
- Administration
- Oral, Intranasal, Buccal, Intravenous, Intramuscular
01
Overview
ACT‑709478 (apinocaltamide) is a potent, selective, orally available and brain penetrating T-type calcium channel blocker in development for epilepsy, including rare pediatric epilepsies. It acts as an anticonvulsant by inhibiting T-type calcium channels. Midazolam is a short‑acting benzodiazepine used for its sedative, anxiolytic, muscle relaxant, anticonvulsant and amnesic properties; it enhances the inhibitory action of gamma‑aminobutyric acid (GABA) at GABA-A receptors. The combination has been studied to assess drug-drug interactions in healthy subjects[3][6][8][1].
- Brand names
- BuccolamBusulfexNayzilamSeizalam
- Other names
- 1838651-58-3N-(1-((5-Cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)phenyl)acetamideapinocaltamida
02
Targets
GABRR (GABA-A receptor subunit rho)CaV3 (Caveolin-3)
Beyond the preview
Go deeper on ACT-709478 + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACT-709478 + midazolam.